Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 341

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 341
---
 with any such policy. Pursuant to Swiss law, NLS adopted a code of business conduct and ethics which covers a broad range of matters including the handling of conflicts of interest, compliance issues and other corporate policies such as insider trading and equal opportunity and non -discriminationstandards. NLS’s code of business conduct and ethics is applicable to all its directors, executive officers and employees. NLS has published its code of business conduct and ethics on its website, www.nlspharma.com. If NLS makes any amendment to the code of business conduct and ethics or grant any waivers, including any implicit waiver, from a provision of the code, NLS will disclose the nature of such amendment or waiver on our website to the extent required by the rules and regulations of the SEC including the instructions to Item 16.B. of Form 20 -F. 188 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS The following unaudited pro forma condensed combined financial information was prepared in accordance with Article 11 of Regulation S -X under the Securities Act of 1933, as amended. The following information and all other information contained in these Unaudited Pro Forma Condensed Combined Financial Statements reflects a notice of a reverse split with the commercial registry of the Canton of Zurich, Switzerland, on September 27, 2024 that became effective in Switzerland on September 27, 2024. The reverse stock split was at a ratio of 1 -for-40 . The following unaudited pro forma condensed combined financial statements combines the historical financial information of Kadimastem and the financial statements of NLS giving effect to NLS’s acquisition of Kadimastem as if the acquisition had been consummated at January 1, 2023. On November 4, 2024, NLS, Merger Sub and Kadimastem entered into the Merger Agreement, pursuant to which (i) Merger Sub will merge with and into Kadimastem, with Kadimastem as the surviving company, and (ii) at the Effective Time of the Merger, each issued and outstanding Kadimastem Ordinary Share, will be exchanged for and automatically converted into the right to receive from the NLS that certain number of fully paid and nonassessable NLS Common Shares as calculated in accordance with the Exchange Ratio. It is anticipated that the initial Exchange Ratio is estimated to result in Kadimastem shareholders holding 85% of the issued and